Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THALASSA: Ianalumab in Sjögren's Disease
NCT07621809Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jul 2026
- Primary completion
- Aug 2029
- Countries
- 8
01
Overview
A Phase 3 trial of ianalumab in Sjögren's syndrome, sponsored by Novartis. Started Jul 2026; status: recruiting.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT07621809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621809.